Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

VYVANSE demonstrated significant efficacy for treatment of ADHD for up to 12 hours post dosing, based on the study's primary efficacy measure, SKAMP-D. Investigators observed a significant difference in patient behavior based upon the average of investigator ratings on the Swanson, Kotkin, Agler, M-Flynn and Pelham Rating Scale deportment (SKAMP-D) scores across eight classroom sessions held during a 12-hour treatment day between patients who received VYVANSE and patients who received Adderall XR, both compared to placebo. The SKAMP-D is a standardized, validated classroom assessment tool used for evaluating the behavioral symptoms of ADHD and higher SKAMP-D ratings reflect greater impairment.

Patients in the study taking VYVANSE also demonstrated significant improvement in math problems attempted as compared to placebo, as measured by the Permanent Product Measure of Performance (PERMP) Derived Measures. When patients were observed at the 12-hour time period, the LS mean change in PERMP math problems attempted from the first measurement was 49 for patients taking VYVANSE and 22 for patients taking Adderall XR, compared to -24 for placebo. PERMP is an age-adjusted collection of math problems that provides an objective measure of performance based on the number of attempted and completed math problems. This study was not designed as a comparative trial between active treatments.

Low Interpatient Variability Demonstrated

In this study, pharmacokinetic parameters were also measured, which found that the coefficient of variance for time to maximum drug concentration for VYVANSE and Adderall XR were 15.33 and 52.77, respectively. The coefficient of variance is a measure used to determine how much variance there is in the data, with smaller numbers indicating less variability. The coefficient of variance of maximum observed drug concentration for VYVANSE and Adderall XR were 20.34 and 43.96, respectively. The relationship between pharmacokineti
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Packaging Coordinators, Inc. (PCI) is pleased to announce it ... Services Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... United Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug ... form manufacturing, as well as Clinical Packaging, Labeling, and ...
(Date:7/30/2014)... -- Hospira, Inc. (NYSE: HSP ), the ... technologies, today reported results for the second quarter ... quarter were $1.1 billion and adjusted* diluted earnings ... items as described later in this press release ... Accepted Accounting Principles (GAAP) basis, second-quarter 2014 diluted ...
(Date:7/30/2014)... July 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... will participate in the Jefferies 2014 Boston Healthcare Summit ... conference will occur on August 6, 2014 and will ... PDL BioPharma manages a portfolio of patents ... al. antibody humanization patents and license agreements with various ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... want to help their preschooler shed excess pounds may want ... Youngsters whose parents joined them in a supervised behavioral modification ... in a traditional child-only program (an average difference of about ... losing almost 15 pounds over two years, according to the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The family ... bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... thinner, Bernstein Liebhard LLP reports. According to the complaint, ... District of Vermont on July 25th, the decedent had ... suffered an irreversible brain bleed that ultimately led to ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
(Date:7/30/2014)... McLean, VA (PRWEB) July 30, 2014 ... its 2014-2015 Board of Directors. Sandra Aiken Chack will ... this month at the EDNF 2014 Annual Learning Conference ... National Foundation has an ambitious agenda ahead of us. ... Clinical Care & Research at the Greater Baltimore Medical ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and ... 4 p.m. to 7 p.m. Wednesday, August 6 at ... Livonia, MI 48152). The event will feature Detroit Red ... music, snacks and local public safety officials. Kohl’s will ... of Michigan Foundation. , The gift supports Kohl’s ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... Paralleling the nation,s efforts to find ways to expand ... care, Concierge Choice Physicians (CCP) announced in ... physicians care for more than 250,000 patients in 12 states - ... Pioneering the concept of hybrid concierge medicine, CCP offers primary care ...
... EAST HAMPTON, N.Y., July 8 The Max Cure Foundation ... cancer causes -- announced today its first charity benefit, the ... day, to take place on Saturday, August 22, from 2:00 ... grounds of the East Hampton Indoor Tennis Club, 175 Daniels ...
... 8 Insulet Corporation (Nasdaq: PODD ), ... that the Company is introducing an environmentally friendly disposal ... Eco-Pod program will reduce the impact of used Pods ... landfills. It is the industry,s first program for ...
... the most famous hotels in Coconut Grove, Florida is now offering ... , In the spirit of game shows of yesterday and today, ... Deal special. It,s simple...call the hotel, mention the Let,s Make a ... suites...the hotel may counter with a Deal or No Deal offer, ...
... July 8 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended June 30, 2009, on Thursday, August 6, ... a conference call and webcast on Thursday, August 6, ... Company,s second quarter results and current corporate developments. The dial-in number ...
... July 8 You,ve just waited through the longest two minutes ... to be positive. After catching your breath, you realize the only ... same again. That,s because you,ve just learned you,re pregnant! This discovery ... mind, and you know you need fast answers. That,s when you ...
Cached Medicine News:Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 2Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 2Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 4Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 5Health News:Insulet Establishes Eco-Friendly Disposal Program for the OmniPod(R) Insulin Management System 2Health News:A Unique Rhythm In The Heart Of Coconut Grove, Florida 2Health News:Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:A Bundle of Joy Brings a Bundle of Questions - Life123.com Delivers the Answers! 2
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... REA kit measures the biologically active form ... B6 is a valuable prognostic marker for ... low plasma vitamin B6 level and Coronary ... transamination reactions of homocysteine to cystathionine and ...
... for use with 4, 8, or 12 channel ... of nearly all of the solution. Corners have ... of natural virgin polystyrene containing no regrinds. Sterile ... irradiation. Dimensions: 78 mm W x 152 mm ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: